Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers
T.C. van Sprundel(Leiden University Medical Center), Rob A.�E.�M. Tollenaar(Leiden University Medical Center), Christi J. van Asperen(Loyola University Medical Center), Matti A. Rookus(The Netherlands Cancer Institute), Richard M. Brohet(The Netherlands Cancer Institute), Marjanka K. Schmidt(University of Cambridge), Laura J. van’t Veer(University of California, San Francisco), Emiel J. Rutgers(Oncode Institute)
Cited by 291
Related Papers
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition
|New England Journal of Medicine|2004|1.7k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
|Nature Genetics|2013|1.1k